Abbreviated hormone replacement therapy trial answers some questions, raises new ones. The Women's Health Initiative is no longer testing the most widely prescribed estrogen and progestin combination--but the study's job is far from over.
D000328:Adult; D000367:Age Factors; D004338:Drug Combinations; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects*; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D018570:Risk Assessment; D014481:United States; D016387:Women's Health
D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); C466383:Prempro; D017258:Medroxyprogesterone Acetate